It's time for FierceMedicalDevices (and the whole Fierce crew) to take a breather for the holiday season. But before we do, let's reflect on some of the major trends that affected the med tech industry over the past 12 months.
As we near the end of 2013, one thing is clear: The FierceMedicalDevices stories that propelled the highest levels of web traffic this year reflect the med tech industry at its best and worst.
Despite renewed investor fervor and no shortage of promising technologies, medical device outfits had so far been largely loathe to join in on the biotech IPO revival. Now that LDR has bagged an over-allotted, top-of-its range debut, is it time for med tech's big moment?
After two delays, a European Parliament committee is scheduled to vote Sept. 25 on tougher new device regulations. Across the Atlantic, at the AdvaMed 2013 conference in Washington, D.C., at least one industry insider joked the vote could be delayed again. That's even before a full EU parliament vote predicted months from now. Read more >>
Time is at a premium. But, Omar Ishrak told FierceMedicalDevices, Twitter has helped him enhance his role as Medtronic's leader and as a stakeholder in the healthcare industry.
Israel is home to nearly 700 medical device outfits, with companies in all of the industry's in-demand markets. So how did a country about the size of New Jersey with roughly the population of Virginia become a go-to medical technology breeding ground?
Industry lobbying groups want you to know that the 2.3% medical device tax has cost companies a combined $1 billion (and rising) since it kicked in on Jan. 1, 2013.
Germany's Activaero is raising money and readying a CE mark filing for its first drug-device combo treatment, targeted to address severe asthma.
In 15 years, Germany's Epigenomics has experienced a heady series of ups and downs. The Berlin-based diagnostics company went public on the Frankfurt stock exchange in 2004 and raised €41.6 million. It merged with a Seattle operation that is now its U.S. arm and gained CE marks for a colon cancer early-detection diagnostic and a lung cancer confirmatory assay. But over the last two years, there was also the restructuring. Read more >>
The company's NanoTherm Therapy is CE marked since 2010 to fry tumors from the inside out, but without major clinical data available befitting a traditional drug therapuetic, faces obstacles from the oncology community.